The FDA has expanded the approval for enzalutamide (Xtandi) to include the treatment of men with chemotherapy-naive metastatic castration-resistant prostate cancer.
Silas Inman, OncLive
Advertisement
Articles by Silas Inman, OncLive
Pertuzumab (Perjeta) in combination with trastuzumab and chemotherapy has become the first FDA-approved neoadjuvant treatment for patients with breast cancer.
Advertisement
Latest Updated Articles
- Pre-Chemo Enzalutamide Approved for Metastatic Castration-Resistant Prostate Cancer
Published: September 11th 2014 | Updated:
FDA Approves Neoadjuvant Pertuzumab RegimenPublished: October 1st 2013 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Estradiol-Containing MHT May Impact Alzheimer Disease-Related Biomarkers in Postmenopausal Women
2
World Standards Week 2025: Advancing Quality and Patient Safety Standards to Shape Pharmacy Practice and Innovation
3
CHEST 2025: Exploring the Link Between GLP-1 Receptor Agonists, Type 2 Diabetes, and Asthma Risk
4
MHT Use Can Affect Cognitive Health Depending on Administration Method
5
